As of December 31, 2021, Acura Pharmaceuticals, Inc. carries a market capitalization of 32.55M, placing it among publicly traded companies globally. Its enterprise value stands at 32.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 32.55M |
| Enterprise Value | 32.68M |
As of December 31, 2021, Acura Pharmaceuticals, Inc. has 65.09M shares outstanding.
| Shares Outstanding | 65.09M |
These figures are as of December 31, 2021. The price-to-sales ratio is 18.12, and the price-to-book ratio stands at 182.85.
| PS Ratio | 18.12 |
| PB Ratio | 182.85 |
| P/TBV Ratio | 182.85 |
| P/FCF Ratio | -38.16 |
| P/OCF Ratio | -38.16 |
These figures are as of December 31, 2021. The EV/Sales ratio of 20.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 32.68M versus a market cap of 32.55M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 20.91 |
As of December 31, 2021, Acura Pharmaceuticals, Inc. maintains a current ratio of 0.72, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 112.36, indicating elevated leverage, while an interest coverage ratio of -5.62 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.72 |
| Quick Ratio | 0.43 |
| Debt / Equity | 112.36 |
| Debt / EBITDA | -0.18 |
| Interest Coverage | -5.62 |
These figures cover the twelve months ended December 31, 2021. Return on assets (ROA) is negative at -67.72, reflecting losses generated across the asset base. The company generates approximately 130,250.00 in revenue per employee across its workforce of 12.00, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -67.72 |
| Revenue Per Employee | 130,250.00 |
| Employee Count | 12.00 |
As of the close on November 16, 2026, Acura Pharmaceuticals, Inc.'s stock has declined approximately 25.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| 52-Week Price Change | -25.00% |
Over the twelve months ended December 31, 2021, Acura Pharmaceuticals, Inc. generated 1.56M in revenue and converted that into -879,000.00 in net income, yielding earnings per share of -0.02. EBITDA reached -1.12M, while operating income came in at -1.21M.
| Revenue | 1.56M |
| Operating Income | -1.21M |
| Pretax Income | -879,000.00 |
| Net Income | -879,000.00 |
| EBITDA | -1.12M |
| EBIT | -1.21M |
| Earnings Per Share (EPS) | -0.02 |
As of December 31, 2021, Acura Pharmaceuticals, Inc. holds 65,000.00 in cash and equivalents against 200,000.00 in total debt, resulting in a net debt position of 85,000.00. Total book value stands at 178,000.00, with working capital of -143,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 65,000.00 |
| Total Debt | 200,000.00 |
| Net Debt | 85,000.00 |
| Equity (Book Value) | 178,000.00 |
| Working Capital | -143,000.00 |
Acura Pharmaceuticals, Inc. produced -742,000.00 in operating cash flow over the twelve months ended December 31, 2021.
| Operating Cash Flow | -742,000.00 |
| Free Cash Flow | -742,000.00 |
| FCF Per Share | -0.01 |
These figures cover the twelve months ended December 31, 2021. The operating margin of -77.67 and net profit margin of -56.24 provide insight into operational efficiency.
| Operating Margin | -77.67 |
| Pretax Margin | -56.24 |
| Profit Margin | -56.24 |
| EBITDA Margin | -71.91 |
These figures cover the twelve months ended December 31, 2021. Free cash flow yield is negative at -2.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.21, meaning Acura Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -1.21 |
| FCF Yield | -2.62 |
Acura Pharmaceuticals, Inc.'s most recent stock split took place on August 28, 2015 with a 5:1 split ratio.
| Last Split Date | 8/28/2015 |
| Split Ratio | 5:1 |
As of December 31, 2021, Acura Pharmaceuticals, Inc. has an Altman Z-Score of -609.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -609.43 |